The Centers for Medicare & Medicaid Services (CMS) home health final payment rule came in much more positive for providers than the proposed rule.

Providers will receive a 0.8% aggregate increase to payments in CY 2024, which will have a material and beneficial impact on the bottom lines of publicly traded home-based care companies.

At the same time, CMS is still implementing permanent, negative behavioral adjustments. CMS is also claiming it overpaid providers by billions of dollars over the last few years, and that it plans to claw that money back at some point.

The top home health companies will continue to advocate against CMS’ methodologies in hopes that Congress will step in to mitigate future cuts. But for now, a 0.8% increase for CY 2024 is at least better than the 2.2% aggregate decrease that was proposed.

“Providers that budgeted for the proposed rule got a boost from the final payment rule,” says Ben Bogan, partner and managing director at Stoneridge Partners. “M&A should tick up as buyers have more certainty on what payment will look like, at least for the next year.”

The S&P was down 2.2% in October. The HHI was down 5.52%, while the PAI was down 0.3%.

Home Health Index

The final rule’s impact will be felt more in November and December, but it’s already evident how it will affect dollars and cents for Enhabit Inc. (NYSE: EHAB) and Amedisys Inc. (Nasdaq: AMED).

Specifically, the change between the proposed and final rule is a $26 million boost for Amedisys and a $18 million boost for Enhabit Inc. (NYSE: EHAB).

That was much needed for Enhabit, which was down 34.43% in October. The company is undergoing a strategic review that could result in a merger or sale.

Conversely, Amedisys was down just 2% in October. UnitedHealth Group’s (NYSE: UNH) acquisition of the company is still pending, and that deal likely won’t reach a result until next year.

While Enhabit’s stock price has declined significantly since its IPO in June of last year, the recent turbulence was likely driven by the company entering into a limited waiver agreement with Wells Fargo Bank (NYSE: WFC).

That turbulence abated a bit toward the end of October, as Enhabit had the chance to explain itself. The company also scored new Medicare Advantage contracts in the third quarter and had a solid streak of hiring: 166 new net nurses, a number that pleased its leaders.

“Our home health team continues to do a great job managing productivity and optimization of our clinical staff,” Enhabit CEO Barb Jacobsmeyer said during the company’s third-quarter earnings call. “Our cost per visit increased 1.1% year over year. Improved nursing productivity and optimization offset the impact of merit and market increases for clinical staff.”

Post-Acute Care Index

The PAI had another lackluster month as well. The Pennant Group (Nasdaq: PNTG) was down 2.39%. Addus Homecare Corporation (Nasdaq: ADUS) was down 7.97%.

Aveanna Healthcare Holdings (Nasdaq: AVAH) was up 13.7%, but accounts for a small percentage of the overall PAI. Its stock price rose from 1.19 to 1.38.

Relatively new to the public market, Aveanna is trying to gain its footing by shifting its clinical capacity to “preferred payers” across all of its segments. In essence, they will accept patients under payers that reimburse fairly for home-based care services.

“Our preferred payer relationships benefited from accelerated caregiver hires of approximately three times more than our other payers, and we continue to experience staffing rates approximately 20% to 25% greater with significantly higher patient admissions,” Aveanna CEO Jeff Shaner said on the company’s third-quarter earnings call. “These positive labor trends have continued into the fourth quarter, and further validate our preferred payer strategy. Preferred payers reimburse us a fair rate, and we pay market competitive wage rates, while also earning value-based payments for achieving positive clinical outcomes and improved caregiver capacity.”

The Pennant Group, though down slightly month over month, has continued to acquire home health and hospice agencies on a regular basis.

Like other prominent home- and community-based services (HCBS) providers, Addus is still waiting on what could be a very impactful final rule from CMS. If CMS goes with its early 2023 proposal, providers would be mandated to direct 80% of reimbursement for HCBS toward caregiver wages.

“At this time, CMS continues to review the more than 2,000 comments submitted to the proposal before issuing a final rule,” Addus CEO Dirk Allison said on the company’s third-quarter earnings call. “The comments submitted to CMS, including those from a broader array of state Medicaid agencies, overwhelmingly call for the administration to rescind the part of the proposed rule requiring that 80% of the Medicaid payment providers go to direct caregiver wages.”

Quote of the Month

“Integrated palliative care is patient-centered care that recognizes that pharmacological interventions are extremely useful, but sometimes can also produce overwhelming side effects,” Kozak said. “By using integrative therapies along with conventional pharmacological interventions, we can frequently decrease the dosage of drugs, decreasing side effects and providing a higher quality of life.”

Leila Kozak, director of the Integrative Palliative Care Institute

Read the Full Article Here: How Providers Can Develop a Culture of Integrative Palliative Care

See It To Believe It!

The Stoneridge Partners Home Health Index (HH Index) is updated monthly and measures the performance of these two publicly traded home health companies, all listed on the NASDAQ:

*NOTE: LHC Group was officially delisted from the Nasdaq when UnitedHealth Group’s (NYSE: UNH) acquisition of it was finalized. While LHC Group is now gone from the HHI, Enhabit has been added in the past year. The numbers below are reflected as such.

  • Amedisys (AMED)
  • Enhabit (EHAB)

Here are the results of the stock prices for the past two years:

Company 10/31/23 1 mos change YTD change 10/31/22 10/31/21
Amedisys 97.59 -2.04 +9.52% 97.59 169.34
Enhabit 7.37 -34.43% -44.00%
HH Index* 49.43 -5.52% -59.69% 132.35 151.97
S&P 4193.80 -2.20% +8.15% 3871.98 4605.38
Addus 78.90 -7.38% -20.70% 102.42 93.50

Although we track the performance of Addus, they are not included in our HH Index because very little of their revenue comes from Medicare.

Enterprise Value (EV)

EV (in M) 2023 2022 2021
Amedisys 3400 3720 5720
Enhabit 9523
HH Index Total 4352 9730 1033
Addus 1400 1820 1400

Enterprise Value (EV), aka Selling Price, as Percent of Revenue

Company 2023 2022 2021
Amedisys 153% 167% 260%
Enhabit 90%
HH Index Average* 122% 215% 238%
Addus 140% 201% 173%

The Stoneridge Partners Post-Acute Care Index is updated monthly and measures the performance of these six publicly traded post-acute care companies, all listed on the NASDAQ:

  • Aveanna (AVAH)
  • Amedisys (AMED)
  • Addus (ADUS)
  • The Pennant Group, Inc. (PNTG)
  • Enhabit (EHAB)
  • Brookdale Senior Living Inc. (BKD)

Here are the results of the Post-Acute stock prices for the past two years:

Company 10/31/23 1 mos change YTD change 10/31/22 10/31/21
Amedisys 91.49 -2.09% +9.52% 97.59 169.34
Addus 78.90 -7.97% -20.70% 102.42 93.50
Pennant 10.87 -2.39% -1.00% 12.31 25.57
Brookdale 3.90 -5.90% +42.86% 4.47 6.50
Enhabit 7.37 -52.51% -44.00% 12.42
Aveanna 1.38 +13.77% +76.92% 1.39

Enterprise Value (EV)

EV (in M) 2023 2022 2021
Amedisys 3400 3720 5720
Addus 1400 1820 1400
Pennant 6433 6657 1010
Brookdale 518 561 620
Enhabit 9523
Aveanna 1580

Enterprise Value (EV), aka Selling Price, as Percent of Revenue

Company 2023 2022 2021
Amedisys 153% 167% 260%
Addus 140% 201% 173%
Pennant 128% 147% 240%
Brookdale 179% 212% 204%
Enhabit 90%
Aveanna 86%

This graph displays Post-Acute Care Index performance starting late 2019.

The above calculations are based on selling price being defined as Enterprise Value (EV), with data provided by Capital IQ. Enterprise value is defined as market cap plus debt, minority interest and preferred shares, minus total cash and cash equivalents. EBITDA is calculated using methodology which may differ from that used by a company for its reporting. (Home Health Index December 2023 | Stoneridge Partners)

Recent Transactions From Around The Country

  • Texas-based Choice Health at Home LLC has acquired Lumicare Hospice, growing its presence in two current markets while establishing services in a new state.

  • American Health Staffing Group has acquired PediaStaff, a leading provider of pediatric therapy and educational staffing services, to expand its specialized healthcare staffing offerings.

  • The Ensign Group, Inc. announced today that it acquired the real estate and operations of Champions Healthcare at Willowbrook.

  • The Pennant Group, Inc. announced that it has acquired Guardian Hospice and Guardian Hospice of Oklahoma.

SOLD by Stoneridge!!!

  • Stoneridge Partners is proud to announce the successful sale of a Home Healthcare Agency in Virginia.
  • Stoneridge Partners is proud to announce the successful sale of a Home Healthcare Agency in Florida.

View Stoneridge closed transactions on our website

Exclusively Listed For Sale By Stoneridge Partners.

Do you know of any acquisitions that have taken place? We are interested in your comments. Contact us at Stoneridge Partners.

$9M+ in revenue with $1.8M in EBITDA.  4 locations with 30 years in the community. Strong tenured staff conducting over 27,000 appointments annually.  CON state...

 Other /  North Carolina

Hospice.  100+ ADC.  Accredited.  No CAP or regulatory issues.

 Hospice /  Pennsylvania

$5M in revenue.  Located in Northern/Richmond VA.  Health system-owned Medicare home health and hospice.  Growing organization.

 Home Health

Non-medical Home Care agency.  $2M+ in revenue.  Medicaid.  Profitable.

 Home Care /  Tennessee

Non-medical Home Care agency.  $3M+ in revenue.  Multiple offices.

 Home Care /  Pennsylvania

Hospice.  100+ ADC.  Multi-location.  No CAP or regulatory issues.

 Hospice /  Texas

Large multi-discipline pediatric therapy practice.  $5+M in revenue.  Multiple offices with a wide geographical footprint.  Full compliment of management and staff in place.

 Other /  Multi-State

Medicare-certified home health.  Opportunity to establish home health presence in Texas.  Minimal census.

 Home Health /  Texas

$14.9M in revenue with $3M of EBITDA.  Second largest residential treatment provider for SUD in KY.  Over 350 beds for residential, PHP, IOP, and OP...

 Behavioral Health /  Kentucky

$4.1M+ in revenue with $1.7M+ of EBITDA.  Community-based outreach program offering mental health services to primarily children and adolescents.  High barrier to entry; accreditation required....

 Behavioral Health /  Ohio

$4.5+M Houston-based Medicaid home care company.  Established 13 years ago.  Excellent HHSC contracts are in place, resulting in an impressive bottom line.  Fully staffed.

 Home Care /  Texas

Non-medical home care franchise.  $2M in revenue.  60% private pay.  20% EBITDA.  Houston market.

 Home Care /  Texas

Medicare/Medicaid-certified home health agency.  $1.4M in revenue.  District 9.  Profitable.  Accredited.

 Home Health /  Florida

Behavioral health, therapy, and educational services business.  $1.8M in revenue with over $600,000 EBITDA.  Services include ABA, early intervention services to children aged 0-21, and...

 Behavioral Health /  Pennsylvania

Home Care Agency.  $12M in revenue.  97% Medicaid.  Highly profitable agency with strong growth trajectory.

 Home Care /  Kansas

$3.2 million in revenue.  JCAHO accredited Home Health company.  Showing remarkable growth trends and is very profitable.

 Home Health /  Texas

Home Health & Hospice with $4.5M in revenue.  Medicare/Medicaid certified.  Excellent growth potential in large service area.

 Other /  Arizona

Hospice with $2.4M+ in revenue.  Medicare/Medicaid certified.  Full complement of staff in place.

 Hospice /  Texas

Home care agency.  $30M+ in revenue.  95% Medicaid.  Platform opportunity.

 Home Care /  New Mexico

$3M pediatric agency in Chicago.  Long-term management in place.

 Home Health /  Illinois

Medicaid-certified home care.  Minimal census.  Opportunity to establish home care presence in Texas.

 Home Care /  Texas

Hospice business.  Low census.  The license covers all of Clark County (Las Vegas and Henderson)

 Hospice /  Nevada

Non-medical home care franchisee.  $9.6+M in revenue.  50% Medicaid/30% Private Pay/ 14% VA/ 6% Misc.  Experienced management team to stay post-transition.

 Home Care /  Multi-State

Hospice.  45+ ADC.  Rio Grande Valley.  No CAP or regulatory issues.

 Hospice /  Texas

$2M revenue home care agency.  100% private pay.  Primarily non-medical.  Skilled designation, not Medicare-certified.  W-2 caregivers.  Region 8.  Accredited.

 Home Care /  Florida

Profitable private-duty home health agency in Northern Virginia.  $1.5M in revenue.  20+ years in the community.

 Home Health /  Virginia

Profitable home care franchise with consistent sales growth.  Revenue of $1.3M.  Great reputation within the community.

 Home Care /  Iowa

$40M+ home care agency with 20+% AEBITDA.  Primarily private-duty, non-medical (90%).  Medicaid waiver programs.  40% family caregivers.  Multiple locations.

 Home Care /  Pennsylvania / Popular

Medicare-certified home health agency.  Houston/Kingwood area.  Approximately $600k in revenue.  Accredited.

 Home Health /  Texas

Medicare-certified home health agency. District 7. Census of approximately 30 patients. Accredited.

 Home Health /  Florida

Medicare home health agency.  Health system relationship.  Rare KY CON opportunity, multiple counties

 Home Health /  Kentucky / Popular

Home health with $8M in revenue.  Medicare/Medicaid-certified.  90+% traditional Medicare/episodic.  Services central Texas and licensed for entire state.  Strong management team in place.

 Home Health /  Texas / Popular

Medicare-certified home health agency.  Houston-area.  Minimal census.

 Home Health /  Texas / Popular

Medicare-certified home health agency.  District 3.  Approximately $700k in revenue.  Accredited.

 Home Health /  Florida

Medicare-certified home health agency.  District 5.  Minimal census.  Accredited.

 Home Health /  Florida

Home Health Index November 2023 | Stoneridge Partners

From Ben Bogan, Publisher of “Home Health Index.” Ben can be reached at [email protected] or (239) 561-0826, and toll-free at 800-218-3944. Previous editions of this monthly newsletter can be searched for at the bottom of the home page of the Home Health Index.